Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
about
Nomograms for predicting recurrence and survival of invasive pathological stage IA non-small cell lung cancer treated by video assisted thoracoscopic surgery lobectomy.Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration.Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series.Mass spectrometry-based serum peptidome profiling accurately and reliably predicts outcomes of pemetrexed plus platinum chemotherapy in patients with advanced lung adenocarcinoma.Appropriateness of imaging for lung cancer staging in a national cohortClinical Outcomes of Patients with Rare and Heavily Pretreated Solid Tumors Treated according to the Results of Tumor Molecular Profiling.PUREAIR protocol: randomized controlled trial of intensive pulmonary rehabilitation versus standard care in patients undergoing surgical resection for lung cancer.Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapyPharmacoeconomic analysis for pemetrexed as a maintenance therapy for NSCLC patients with patient assistance program in China.Managing the genomic revolution in cancer diagnostics.EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50.Circulating microRNAs as novel biomarkers of ALK-positive nonsmall cell lung cancer and predictors of response to crizotinib therapy.Nab-Paclitaxel in combination with Cisplatin Versus Docetaxel Plus Cisplatin as First-Line Therapy in Non-small Cell Lung CancerPrognostic Value of Serum Proteomic Test and Comorbidity Index in Diversified Population with Lung Cancer.Editorial on: multidisciplinary therapy of marginally operable stage IIIA non-small cell lung cancer.Spotlight on landmark oncology trials: the latest evidence and novel trial designs.Spotlight on brigatinib and its potential in the treatment of patients with metastatic ALK-positive non-small cell lung cancer who are resistant or intolerant to crizotinibSuppression of the FA pathway combined with CHK1 inhibitor hypersensitize lung cancer cells to gemcitabine.Medical Oncologists' Experiences in Using Genomic Testing for Lung and Colorectal Cancer Care.Non-invasive diagnostic platforms in management of non-small cell lung cancer: opportunities and challenges.Moving more potent and less toxic options to the frontline in the management of advanced lung cancer.Tonsillar metastasis of nonsmall cell lung cancer with G719S mutation in exon 18: A case report.Molecular Targets in Non-Small Cell Lung Cancer.Predictive clinical parameters for the response of nivolumab in pretreated advanced non-small-cell lung cancer.Prophylactic cranial irradiation or no prophylactic cranial irradiation in metastatic small cell lung cancer: is it a relevant question once again?Identification of a New Potent Inhibitor Targeting KRAS in Non-small Cell Lung Cancer Cells.Semi-rigid single hook localization the best method for localizing ground glass opacities during video-assisted thoracoscopic surgery: re-aerated swine lung experimental and primary clinical results.Development of pulmonary Langerhans cell histiocytosis in a patient with established adenocarcinoma of the lung.Differences in skeletal muscle loss caused by cytotoxic chemotherapy and molecular targeted therapy in patients with advanced non-small cell lung cancer.Bevacizumab in combination with different platinum-based doublets in the first-line treatment for advanced nonsquamous non-small-cell lung cancer: A network meta-analysis.Value of (18)F-FDG PET/CT for predicting EGFR mutations and positive ALK expression in patients with non-small cell lung cancer: a retrospective analysis of 849 Chinese patients.Anaplastic Lymphoma Kinase Testing: IHC vs. FISH vs. NGS.Multicenter study of diagnostic procedures, genetic aberration analysis, and first-line treatment of lung cancer in Jiangsu Province, China.Multicentric retrospective analysis of platinum-pemetrexed regimens as first-line therapy in non-squamous non-small cell lung cancer patients: A "snapshot" from clinical practice.Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.Microarray profile of circular RNAs identifies hsa_circ_0014130 as a new circular RNA biomarker in non-small cell lung cancer.Long-term progression-free survival in an advanced lung adenocarcinoma patient harboring EZR-ROS1 rearrangement: a case report.MicroRNAs as regulators of cisplatin-resistance in non-small cell lung carcinomas.YAP regulates PD-L1 expression in human NSCLC cells.
P2860
Q33639243-EAB65A6A-7843-463A-A24D-9398151E44BAQ33743535-1770CBE4-035B-4F3F-9431-290F45BA668DQ33763622-53B72816-0D46-49FC-82A1-C263341C39B4Q33778668-758CE941-8213-4357-91EB-AE56C54804DEQ34332850-04A9F558-47A1-4022-BD67-25C6C5CF1DDEQ37150582-588C6959-0BC8-48C1-9C2D-539A546B149DQ38369354-78D260D1-06F2-4A19-AAE3-FE27586A0253Q38598893-544E4288-2886-41B3-9911-F06D57C2FFD1Q38603487-B47EA856-E4F0-450A-A2C2-B5069156AF7BQ38714606-CFCE31AC-2A16-4591-9B4A-6B0C961E5920Q41107790-AD22E00A-4C80-4FF8-9ECC-D5BAE74B7C7AQ41233416-F10BE632-B0D6-4968-929A-17F7AD44A0E4Q41536996-86BAC317-8B92-40F5-8D5A-8C681FEB1BFFQ41670014-6C6E42F1-16A6-4AC9-A083-10A2EFAFFAC9Q42342006-9931E8F3-1122-4B2D-97C3-C3A2313B0DABQ42343618-580674D1-6FAE-456B-894C-F5AE035999B3Q42673256-BE0EEFDA-277D-408C-B700-E2A99145FDE3Q43973311-788879F6-8C0B-46DE-B85B-0620D370A9A7Q43994049-2D4036CE-9279-4167-90B4-C9C559F7DF53Q45891469-B2F7D437-70C5-4A4E-A401-8DE9F47C88ABQ47108604-9CA01210-05B9-4275-8020-E2DAE20454E0Q47125750-2C3B23DA-1DB6-461E-B3A2-678F409F4C98Q47141828-DD4F9917-21CB-4183-945B-42BC02CF342BQ47142109-062B7C62-6497-42F3-BB36-1E589806D053Q47148981-A55C679F-6970-40C4-84ED-76E83373D154Q47155582-7D2A1FBE-ED3C-4B0B-87DC-EA2D56FF9405Q47173885-65FC64DA-506A-46E2-A076-4908E20FD098Q47274741-173CCB9B-D356-42CD-8ADC-436F4134D4B4Q47418565-18A4DB2A-9B68-4FB2-B337-1AADD32EE73FQ47420701-69948925-0753-47A5-A59C-97198FDC9A98Q47574237-FA908C88-1776-4ABC-A4D1-35C599F9CB04Q47578326-C0581D2A-4FF9-48C6-92EF-2B10A09BBAE0Q47654942-6AF6B1B3-4E6C-4CDD-A12B-4ABA80D428E8Q48126555-DC4DC669-2350-4451-B6AB-8EAB9D80E113Q48369218-7F99621C-9779-45E3-86E5-E896EC3F088DQ48535444-11F59702-F20A-499D-97AE-FB329296D427Q49388126-A4FBC121-6612-4676-A8DF-CACF88F657BEQ49404537-29903E25-E4EA-4A95-AC5D-23B1D0291E88Q49409530-BB271484-6CCB-41D9-9840-F4EEE50FF008Q49569691-FEE35D59-C531-4EE8-A039-6B41FEE38070
P2860
Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.
@en
type
label
Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.
@en
prefLabel
Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.
@en
P2093
P356
P1476
Non-Small Cell Lung Cancer, Ve ...... actice Guidelines in Oncology.
@en
P2093
Billy W Loo
Dara L Aisner
David S Ettinger
Douglas E Wood
Gregory A Otterson
Gregory J Riely
James Stevenson
Jessica Bauman
Karen Reckamp
P304
P356
10.6004/JNCCN.2017.0050
P577
2017-04-01T00:00:00Z